Platelet activation relieves liver portal hypertension <i>via</i> the lymphatic system though the classical vascular endothelial growth factor receptor 3 signaling pathway
<i>Via</i> VEGF-C/VEGFR-3, platelets impede fibrosis, angiogenesis, and mesenteric artery remodeling, ultimately alleviating PHT. Thus, platelet intervention is a therapeutic approach for cirrhosis and PHT.
Authors
- Guangbo Wu (ORCID: https://orcid.org/0000-0001-7123-1867)
- Jiayun Lin
- Qiang Fan (ORCID: https://orcid.org/0000-0002-3059-2436)
- Zheng-Hao Wu
- Haizhong Huo (ORCID: https://orcid.org/0000-0002-1573-9655)
- Xiaoliang Qi (ORCID: https://orcid.org/0000-0002-2480-7242)
- Hongjie Li (ORCID: https://orcid.org/0000-0002-9364-9081)
- Meng Luo (ORCID: https://orcid.org/0000-0003-3975-7476)
- Zhifeng Zhao (ORCID: https://orcid.org/0000-0002-6311-1811)
- Chihao Zhang (ORCID: https://orcid.org/0000-0003-3924-0207)
- Jinbo Zhao (ORCID: https://orcid.org/0000-0002-7806-6072)
- Lei Zheng (ORCID: https://orcid.org/0000-0002-4344-2445)
- Min Chen
- Gu-Qing Luo
- Abudukadier Tuersun
Institutions
- Shanghai Jiao Tong University (CN)
- Renji Hospital (CN)
Publication Details
- Journal
- World Journal of Gastroenterology
- Published
- 2025-02-26
- DOI
- https://doi.org/10.3748/wjg.v31.i10.100194
- Citations
- 4
- Primary Topic
- Genetic and Kidney Cyst Diseases
- Type
- article
- Field-Weighted Citation Impact
- 7.27